No Data
No Data
Express News | Brainstorm Cell Therapeutics Inc - Alignment With FDA on Nur Own Cmc Aspects
Express News | Brainstorm Cell Therapeutics Reaches Alignment With FDA on Cmc Aspects of Phase 3B Nurown® Clinical Trial
BrainStorm Appoints Haro Hartounian as COO
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
Express News | Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.d. as Chief Operating Officer
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the...